The study was led by Sue Shapses, PhD, RD, DFASN, of Rutgers University and Rutgers–RWJ Medical Center. The trial is designed around a calorie reduction strategy paired with either a narrower or typical daily eating schedule. Participants were counseled to cut 500 calories per day to standardize energy intake across groups.

Forty-seven women aged 50–79 were enrolled. All reduced calories, but 26 participants were assigned to restrict eating to a window of fewer than 9 hours per day, while the remaining group maintained an approximately 12-hour window. In practice, the time-restricted group typically ate from about 10 a.m. to 6 p.m., yielding an average eating window of 8.2 hours, compared with 12.3 hours for the control window.

After six months, both groups lost weight—about 15 pounds on average—with no meaningful difference between groups. This allowed the researchers to examine whether cognitive changes track with eating-window compression rather than weight loss per se.

Cognitive testing showed that the shorter-window group improved performance on spatial planning and problem-solving tasks at the end of the weight-loss program. A trend toward fewer errors on memory and learning measures was also observed, although multitasking and reaction-time outcomes did not differ significantly.

Shapses said the effects were modest but meaningful, linking reduced eating windows to improved ability to remember information in everyday contexts and to make fewer errors associated with memory, attention, and problem-solving. Notably, the size of the cognitive improvements increased as the eating window shortened.

Because the trial was small, the authors emphasize the need for larger, more definitive studies. They also plan mechanistic work to explain how early stopping and circadian alignment might influence nutrient-sensing pathways, inflammation, and metabolic health—processes implicated in cognitive aging.

The findings will be presented at NUTRITION 2026, the American Society for Nutrition’s flagship meeting, during the Aging and Chronic Disease (II) Poster Session on Sunday, July 26, from 9:30–10:30 a.m. EDT. The organizers note that abstracts selected for the meeting are not routinely peer-reviewed in the same way as journal articles, so the results should be considered preliminary until published in a peer-reviewed format.

Subject of Research: Time-restricted eating and cognitive outcomes in older women
Article Title: Not provided
News Publication Date: July 26, 2026
Web References: Provided in the original content (abstract PDF and presentation details link)
References: Not provided
Image Credits: Not provided

Keywords: time-restricted eating, dementia risk, cognitive decline, circadian rhythm, older adults, clinical trial, Alzheimer disease, metabolic health, nutrient sensing

The REMINDER program is particularly significant as it targets older adults who are perceived to be at heightened risk for developing dementia. This demographic often faces a unique set of challenges, from chronic health conditions to social isolation, which can exacerbate cognitive decline. As society grapples with an aging population, understanding and addressing these risks becomes paramount. The researchers behind the REMINDER program aim to leverage neuropsychological principles to create an intervention that not only addresses cognitive health but also promotes a holistic approach to well-being.

Central to the REMINDER program’s strategy is the recognition that lifestyle factors play a crucial role in cognitive function. Numerous studies have highlighted how physical activity, nutrition, and social interactions can influence brain health. The researchers have developed a structured yet flexible intervention protocol that integrates these elements, encouraging participants to engage in activities designed to enhance their cognitive resilience. This approach reflects a broader shift in the understanding of dementia prevention, moving away from purely pharmacological solutions to one that embraces lifestyle and behavioral changes.

The randomized controlled trial design of the REMINDER program is particularly noteworthy. This robust methodology is considered the gold standard in clinical research, allowing for the establishment of causal relationships between the intervention and cognitive outcomes. By randomly assigning participants to either the intervention or control group, the researchers can mitigate biases and confounding variables that may otherwise skew the results. This rigorous clinical trial design will provide invaluable data on the effectiveness of the neuropsychological intervention for older adults at risk of dementia.

Moreover, the intervention draws upon a variety of neuropsychological techniques, integrating cognitive training exercises, memory enhancement strategies, and motivational interviewing. These techniques are designed not only to improve cognitive abilities but also to empower participants to adopt healthier lifestyles. Lifestyle modifications are essential because they not only directly influence cognitive health but also enhance emotional well-being and social connectedness, which are crucial for older adults.

The implications of the REMINDER program extend beyond mere academic interest. Fostering a lifestyle that is conducive to cognitive health can significantly impact public health strategies aimed at addressing the dementia crisis. By demonstrating that lifestyle interventions can effectively reduce the risk of cognitive decline, the researchers hope to influence policy decisions related to geriatric care and support services. This could potentially lead to a shift in how healthcare systems prioritize preventive measures for aging populations.

As the trial progresses, the researchers anticipate encountering both challenges and successes that will inform the future of cognitive health interventions. One significant challenge is the adherence to lifestyle changes among participants, which is often a barrier in similar studies. To combat this, the REMINDER program incorporates continuous support mechanisms, ensuring that participants feel supported and motivated throughout the intervention period. This adaptive approach is crucial for sustaining long-term behavioral changes.

Furthermore, the program’s emphasis on community engagement serves to bolster its effectiveness. By fostering connections between participants, caregivers, and community resources, the REMINDER program seeks to create a supportive environment that encourages lifestyle modifications. Such community-based initiatives can amplify the reach of the intervention and promote a culture that values cognitive health and well-being in older adults.

The researchers are also keenly aware of the potential variance in individual responses to the intervention. Cognitive decline is not a uniform experience; thus, tailoring aspects of the program to fit individual needs and preferences is essential. The flexibility of the intervention allows for modifications based on participant feedback, ensuring that it remains relevant and effective across diverse populations. Such personalized approaches are gaining traction in geriatric care, highlighting the necessity of considering unique patient backgrounds and experiences.

In parallel with the anticipated findings of the REMINDER trial, a wealth of literature continues to emerge regarding the impact of lifestyle on cognitive health. The researchers are committed to situating their findings within this broader context, contributing to an evolving understanding of how everyday habits shape brain health. The ultimate goal is to provide actionable insights that can be swiftly translated into practice, fostering a proactive approach to dementia prevention.

While the challenges of dementia are daunting, initiatives like the REMINDER program illuminate promising pathways for intervention. By approaching cognitive health from a holistic perspective, this program seeks to empower older adults to take charge of their cognitive well-being. As the trial unfolds, the researchers are hopeful that their findings will not only validate their intervention but also ignite further interest and investment in lifestyle-based approaches to dementia prevention.

Ultimately, the REMINDER program exemplifies a pivotal shift in how society addresses the challenges of aging and cognitive decline. Through rigorous research and an unwavering commitment to improving the lives of older adults, this trial has the potential to significantly contribute to the dementia prevention landscape. As we continue to advance our understanding of the factors that influence cognitive health, it is initiatives like these that will light the way toward a healthier future for our aging population.

The researchers involved in the REMINDER program believe that the journey towards cognitive health is a collaborative effort that necessitates the engagement of various stakeholders, including healthcare providers, policymakers, and families. As we await the results of this important trial, the anticipation is palpable not just within the research community but also among the millions of individuals and families affected by dementia worldwide. The hope is that the REMINDER program will pave the way for innovative interventions that can genuinely make a difference in the lives of older adults, ensuring that they not only live longer but also enjoy a better quality of life.

Subject of Research: The effectiveness of a neuropsychological intervention for lifestyle modification in older adults at risk of dementia.

Article Title: REMINDER program: a randomized controlled trial protocol of a neuropsychological intervention for lifestyle modification in older adults at risk of dementia.

Article References:

Silva, A.R., Baptista, C., Baldeiras, I. et al. REMINDER program: a randomized controlled trial protocol of a neuropsychological intervention for lifestyle modification in older adults at risk of dementia.
BMC Geriatr (2025). https://doi.org/10.1186/s12877-025-06714-x

Image Credits: AI Generated

DOI: 10.1186/s12877-025-06714-x

Keywords: dementia prevention, lifestyle intervention, cognitive health, older adults, randomized controlled trial, neuropsychological techniques, geriatric care, community engagement.

The research’s foundational insights stemmed from what researchers term a "natural experiment." This situation presented itself following the establishment of a shingles vaccination program that set eligibility based on an individual’s date of birth. Specifically, individuals born before September 2, 1933, were rendered ineligible for vaccination, while those born on or after that date could receive it. This unique arrangement provides a compelling opportunity for comparison, as the ages of individuals in proximity—those around 80 years old—allowed researchers to isolate the impact of vaccination on health outcomes. The nearly identical age segments made it feasible to identify vaccination as the significant variable in determining future dementia diagnoses.

Delving deeper into the study, Dr. Eyting articulated the researchers’ primary objective: to discern a causal relationship between receiving the shingles vaccine and the likelihood of developing dementia. In the realm of health research, merely establishing correlation is insufficient; instead, demonstrating causation is crucial. Econometric techniques, specifically regression discontinuity designs, offer a robust framework through which researchers can derive causal links from observational data. Though familiar to economists, this methodological approach remains underutilized in clinical research, leading Eyting to advocate for its broader application in assessing public health interventions.

The researchers meticulously analyzed health records, examining the correlation between receiving the shingles vaccine and subsequent dementia diagnoses. Remarkably, their findings indicated a 20% reduction in the probability of being diagnosed with dementia over a seven-year period for those vaccinated compared to those who were not. This statistic is not merely an intriguing number; it carries profound implications for dementia prevention strategies and public health policies. Shingles, caused by the varicella-zoster virus, may have further-reaching consequences than previously understood, beyond the immediate discomfort and risks associated with the condition itself.

In this analysis, the multidisciplinary collaboration among the researchers played a pivotal role in the discovery. Dr. Min Xie, co-lead author and postdoctoral researcher at the Heidelberg Institute of Global Health, highlighted how their statistical and economic know-how could bridge the gap between seemingly disparate fields, ushering in innovative approaches to health research. The melding of econometric methods with health data enhances the credibility of findings and pushes the boundaries of traditional medical research, steering it onto uncharted territories where economics and healthcare intersect.

Notably, alongside Eyting and Xie, Dr. Simon Heß from the Vienna University of Economics and Business contributed his extensive experience in econometric methodologies, bolstering the research team’s analytical prowess. The collaborative nature of the study extends even further, with researchers from Stanford University assisting, showcasing the widespread interest and acknowledgment of this potential link between vaccination and neurological health.

The implications of this study could reshape preventative strategies against dementia, a condition affecting millions worldwide. As the global population ages, the prevalence of dementia has surged, leading to a pressing need for effective preventive measures. This research not only provides a potential pathway toward reducing dementia risks but also encourages further investigation into how other vaccinations and health interventions may influence neurological outcomes.

Furthermore, the innovative use of economic modeling in public health research opens numerous avenues for scholars and policymakers alike. By employing rigorous statistical analyses traditionally reserved for economic inquiries, public health officials can glean new insights on intervention effectiveness, patient outcomes, and long-term health trajectories. As such, the findings of this research serve as a clarion call for an integrated approach towards public health initiatives, one that utilizes the full breadth of available methodologies to tackle multifaceted health issues.

The recognition of this study’s contributions extends into the academic community, with Dr. Eyting recently being awarded the 2023 Young Economist Award from the European Economic Association. This honor underscores the potential of their work to resonate beyond immediate health implications, highlighting how interdisciplinary approaches can foster innovation and significantly impact societal challenges.

As further studies emerge from this initial research, the role of vaccinations in preventing conditions beyond their primary objectives must be critically examined. This inquiry will likely expand to encompass other preventive measures and their influence on long-term health outcomes, encouraging a broader dialogue in both medical and economic circles about the intertwined nature of health and well-being.

In conclusion, the study challenging traditional boundaries between health and economics builds a compelling case for deeper exploration into the relationship between vaccines and neurological health, emphasizing the potential for aligning vaccination programs with broader public health goals. As health experts continue to parse the data, the hope is that this research could lead to transformative strategies for dementia prevention worldwide, paving the way toward a healthier, more informed future.

Subject of Research: Vaccination and dementia risk
Article Title: A natural experiment on the effect of herpes zoster vaccination on dementia
News Publication Date: April 2, 2025
Web References: Nature DOI Link
References: Nature (Journal)
Image Credits: Not applicable

Keywords: shingles vaccination, dementia, public health, natural experiment, statistical analysis, causal relationship, interdisciplinary research, econometrics, preventative health strategy.

The research emerged from the National Institutes of Health-supported Systolic Blood Pressure Intervention Trial Memory and Cognition in Decreased Hypertension Study, commonly referred to as SPRINT MIND. This extensive study encompassed 9,361 participants over the age of 50, recruited from more than 100 clinics across the United States and Puerto Rico. Each participant was randomly allocated to either an intensive treatment group, targeting a systolic blood pressure goal of less than 120 mm Hg, or a standard treatment group with a target of less than 140 mm Hg.

Participants engaged in the study for a median duration of seven years, during which cognitive evaluations were meticulously carried out. These assessments were done both through in-person visits and telephone follow-ups, allowing researchers to classify participants into categories based on their cognitive status. The classifications included no cognitive impairment, mild cognitive impairment, and probable dementia. This thorough approach enabled the collection of reliable data regarding the long-term cognitive impacts of varying blood pressure control strategies.

The findings unveiled by the study were impressive. Individuals within the intensive treatment group demonstrated a sustained lower incidence of cognitive impairments compared to their counterparts in the standard treatment group. Notably, they exhibited a significantly reduced rate of mild cognitive impairment, alongside a lower combined incidence of both mild cognitive impairment and probable dementia. This aspect of the research emphasizes not just a fleeting benefit, but a substantial, ongoing advantage to aggressive hypertension management.

Historically, the significance of blood pressure control has often centered on cardiovascular health. In 2015, results from the original SPRINT trial indicated that rigorous blood pressure management could diminish the incidence of cardiovascular diseases and dramatically reduce mortality risk by 30 to 40%. Given the pronounced success and positive outcomes observed, the SPRINT trial was terminated ahead of schedule. However, this early conclusion created some uncertainties regarding the definitive role of intensive blood pressure control in dementia cases, particularly as participants experienced reduced treatment durations compared to the initial study design expectations.

The SPRINT MIND study initially reported findings in 2019 that hinted at positive cognitive outcomes resulting from stringent blood pressure management. Those early results indicated a significantly decreased risk of developing mild cognitive impairment for participants enjoying intensive blood pressure control, with observed benefits extending up to five years after treatment cessation. The new findings from this updated analysis, however, extend that timeline considerably. It reveals that the cognitive benefits persist for at least seven years following the conclusion of intensive treatment.

Dr. David M. Reboussin, a key author of the study and a professor of biostatistics and data science at Wake Forest University School of Medicine, clarified the study’s impactful implications, stating that the results provide compelling evidence supporting the hypothesis that rigorous blood pressure management is a vital strategy for cognitive impairment prevention. This approach is particularly crucial given cognitive decline is a leading factor in diminished independence among older adults. By advocating for lower blood pressure targets, we can promote both improved quality of life and prolonged active life for individuals dealing with hypertension.

As we face an aging population, understanding the intersection between cardiovascular health and cognitive function becomes increasingly pertinent. The SPRINT MIND findings amplify existing literature underscoring the need for preventive healthcare strategies that target blood pressure management. As substantial resources are invested in understanding Alzheimer’s disease and other forms of dementia, blood pressure control emerges as a straightforward yet powerful intervention that can alter the trajectory of cognitive health for many individuals facing hypertension.

These results offer hope for millions, highlighting the potential for everyday medical practice to incorporate aggressive blood pressure management as a standard for preventive care. By prioritizing blood pressure control, healthcare professionals might significantly impact aging populations, ultimately mitigating the risks associated with cognitive decline. This paradigm shift would not only influence individual patient outcomes but could also provide broader public health benefits as we seek to reduce the overall burden of dementia-related conditions.

The scientific community remains vigilant as additional studies and long-term follow-ups will be necessary to fully understand the profound implications of this research on clinical practices. However, the trajectory laid out by SPRINT MIND sets a promising foundation that emphasizes preventive measures and highlights the importance of longitudinal studies in unraveling complex health challenges.

As we delve into this data-rich field, the integration of aggressive blood pressure management into cardiovascular care could reshape how we approach later-life health and cognitive resilience. The application of intensive treatment protocols might redefine expectations for patients with hypertension, carving pathways toward improved living conditions and preserving cognitive health within our aging societies.

In summary, the findings from this major study underscore the relationship between blood pressure regulation and cognitive health outcomes. They serve as a call to action for healthcare systems to prioritize thorough blood pressure management, championing strategies that not only uphold cardiovascular health but also imbue hope for cognitive longevity.

Subject of Research: Blood Pressure Management’s Effect on Cognitive Impairment
Article Title: Long-Term Effect of Intensive vs Standard Blood Pressure Control on Mild Cognitive Impairment and Probable Dementia in SPRINT
News Publication Date: January 21, 2025
Web References: https://school.wakehealth.edu/
References: 10.1212/WNL.000000000021333
Image Credits: Not Provided

Keywords: Hypertension, Dementia, Cognitive Impairment, Blood Pressure Management, Cardiovascular Risk, Cognitive Health

Dementia poses major challenges not only to individuals afflicted with this condition but also to their caregivers and society at large. The economic cost of dementia has been estimated to surpass US$1 trillion worldwide, indicating a critical need for effective treatments that go beyond simply managing symptoms. Recent advancements, like the emergence of lecanemab and donanemab, offer some hope by targeting amyloid plaques—a hallmark of Alzheimer’s disease—but their limited efficacy and rejection by the National Institute for Health and Care Excellence (NICE) for public use illustrate the urgent need for more viable alternatives.

As clinical trials traditionally require extensive time and resources for developing new medications, researchers are increasingly exploring the repurposing of existing approved drugs to accelerate the process. Given their established safety profiles, the adoption of these medications for dementia treatment could pave the way for faster clinical trials. “We urgently need new treatments to slow the progress of dementia,” states Dr. Ben Underwood of the University of Cambridge, emphasizing the potential benefits of using pre-approved drugs for this purpose.

The recent systematic review published in the journal “Alzheimer’s and Dementia: Translational Research & Clinical Interventions” meticulously analyzed 14 studies that leveraged vast clinical datasets to evaluate the relationship between prescribed medications and dementia risk. By pooling data from over 130 million individuals, including 1 million diagnosed cases of dementia, researchers aimed to consolidate findings from various studies, some of which presented inconsistent results regarding specific drugs’ effects on dementia risk.

Addressing the unexpected but significant discoveries, researchers observed a notable correlation between the use of antibiotics, antivirals, and vaccines, and a decreased incidence of dementia. This finding suggests that common forms of dementia may be associated with underlying viral or bacterial infections, indicating an area ripe for further research. The association with vaccines, particularly the BCG vaccine used for tuberculosis, underlines the importance of preventative measures in reducing dementia risk.

Additionally, anti-inflammatory drugs, including over-the-counter options like ibuprofen, were found to be linked with a reduced risk of developing dementia. This insight highlights the increasing recognition of inflammation as a critical factor in various diseases, including cognitive disorders. The role of inflammatory pathways is further underscored by genetic studies that demonstrate how certain genes associated with dementia risk are intertwined with inflammatory responses.

However, the review also revealed conflicting evidence regarding various drug classes, particularly blood pressure medications and antidepressants, with some linked to decreased dementia risk, while others showed increased risk. This inconsistency underscores the complexity of the issue, as the variations in study methodologies, data collection techniques, and the pharmacological actions of individual medications can significantly influence outcomes.

Dr. Ilianna Lourida from the University of Exeter cautions against jumping to conclusions from these associations. She emphasizes that a correlation does not imply causation, stating that conditions like diabetes, known to elevate dementia risk, can obscure the apparent effects of medications. Thus, careful interpretation of the findings is crucial, accompanied by a nuanced understanding of the benefits and risks associated with each drug class.

The pursuit of discovering repurposed drugs for dementia treatment aligns with broader initiatives supported by the UK government, which aims to expedite Alzheimer’s trials through streamlined processes. By harnessing vast health data into focus areas for drug testing, researchers hope to identify and prioritize drugs that show the most promise in combatting dementia effectively.

Through these findings, there is newfound optimism that existing medications might hold the key to slowing down dementia progression. The challenge remains, however, in designing robust clinical trials and ensuring that these potential treatments can reach patients without unnecessary delays, ultimately leading to improved outcomes for those affected by this pervasive and debilitating condition.

As scientists continue to uncover the layered complexities of dementia, the repurposing of existing drugs offers a pragmatic and potentially rapid pathway to new therapies. The research shows that integrating insights from a variety of studies and utilizing large datasets can yield significant advancements in how we approach dementia prevention and treatment.

The hope is that, by redirecting our focus toward these existing medications, researchers may soon bridge the gap in dementia care and provide effective solutions that alleviate the burden on patients and society as a whole. The ongoing investigation into the links between medication use and dementia risk is a pivotal step toward unraveling the mysteries of this condition and finding effective interventions.

Subject of Research: People
Article Title: Data-driven discovery of associations between prescribed drugs and dementia risk: A systematic review
News Publication Date: 21-Jan-2025
Web References:
References: Underwood, BU & Lourida, I et al. Data-driven discovery of associations between prescribed drugs and dementia risk: A systematic review. Alz & Dem; 21 Jan 2025; DOI: 10.1002/trc2.70037
Image Credits:

Keywords: Dementia, Drug studies, Antivirals, Drug research, Antiinflammatory drugs, Alzheimer disease